Nyxoah SA - Ordinary Shares (NYXH)

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System

REGULATED INFORMATION

Nyxoah Provides an Update on Expanded Middle East Presence

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.

                

Nyxoah Announces Upcoming Investor Events

REGULATED INFORMATION

REGULATED INFORMATION

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

INSIDE INFORMATIONREGULATED INFORMATION

REGULATED INFORMATION

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

REGULATED INFORMATION

REGULATED INFORMATIONJune 13, 2025, 7:00am CET / 1:00am ET

                

Nyxoah to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

REGULATED INFORMATION

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

                

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

REGULATED INFORMATIONMay 9, 2025, 7:00am CET / 1:00am ET

Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025